Unrelated cord blood transplantation for thalassaemia: A single-institution experience of 35 patients

T. H. Jaing, I. J. Hung, C. P. Yang, S. H. Chen, H. T. Chung, P. K. Tsay, Y. C. Wen

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Our study was designed to prospectively determine whether or not unrelated cord blood transplantation (CBT) can produce outcomes comparable to related donor transplantation for children with β-thalassaemia. In 35 patients, 40 transplants were performed between October 2003 and September 2009. HLA matching at enrolment was 6/6 (n=8), 5/6 (n=16), 4/6 (n=27), or 3/6 (n=1) by low-resolution HLA-A, -B, and high-resolution DRB1. These patients received non-manipulated grafts without ex vivo expansion or T-cell depletion. The median number of nucleated and CD34+ cells infused was 7.8 × 107/kg (range, 2.8-14.7 × 107/kg) and 4.0 × 105/kg (range, 1.7-19.9 × 105/kg), respectively. The 5-year OS and thalassaemia-free survival after the first transplant were 88.3 and 73.9%, respectively. The cumulative incidence of TRM at 2 years was 11.7%. Fourteen patients developed chronic skin GVHD. Thirty patients were alive and transfusion-independent with a Lansky performance score ≥80% achieved between 6 and 76 months post transplant (median, 36 months). These data compare acceptably with the survival rates of related-donor BMT for thalassaemia and suggest that patients without an available HLA-compatible sibling but who have well-matched unrelated donors should also be considered for CBT.

Original languageEnglish
Pages (from-to)33-39
Number of pages7
JournalBone Marrow Transplantation
Volume47
Issue number1
DOIs
Publication statusPublished - Jan 2012
Externally publishedYes

Fingerprint

Thalassemia
Fetal Blood
Transplantation
Transplants
Tissue Donors
Unrelated Donors
HLA-A Antigens
HLA-B Antigens
Siblings
Survival Rate
T-Lymphocytes
Skin
Survival
Incidence

Keywords

  • cord blood transplantation
  • thalassaemia
  • unrelated donor

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Unrelated cord blood transplantation for thalassaemia : A single-institution experience of 35 patients. / Jaing, T. H.; Hung, I. J.; Yang, C. P.; Chen, S. H.; Chung, H. T.; Tsay, P. K.; Wen, Y. C.

In: Bone Marrow Transplantation, Vol. 47, No. 1, 01.2012, p. 33-39.

Research output: Contribution to journalArticle

Jaing, T. H. ; Hung, I. J. ; Yang, C. P. ; Chen, S. H. ; Chung, H. T. ; Tsay, P. K. ; Wen, Y. C. / Unrelated cord blood transplantation for thalassaemia : A single-institution experience of 35 patients. In: Bone Marrow Transplantation. 2012 ; Vol. 47, No. 1. pp. 33-39.
@article{dd56f3c2389f4541a6008730761583d6,
title = "Unrelated cord blood transplantation for thalassaemia: A single-institution experience of 35 patients",
abstract = "Our study was designed to prospectively determine whether or not unrelated cord blood transplantation (CBT) can produce outcomes comparable to related donor transplantation for children with β-thalassaemia. In 35 patients, 40 transplants were performed between October 2003 and September 2009. HLA matching at enrolment was 6/6 (n=8), 5/6 (n=16), 4/6 (n=27), or 3/6 (n=1) by low-resolution HLA-A, -B, and high-resolution DRB1. These patients received non-manipulated grafts without ex vivo expansion or T-cell depletion. The median number of nucleated and CD34+ cells infused was 7.8 × 107/kg (range, 2.8-14.7 × 107/kg) and 4.0 × 105/kg (range, 1.7-19.9 × 105/kg), respectively. The 5-year OS and thalassaemia-free survival after the first transplant were 88.3 and 73.9{\%}, respectively. The cumulative incidence of TRM at 2 years was 11.7{\%}. Fourteen patients developed chronic skin GVHD. Thirty patients were alive and transfusion-independent with a Lansky performance score ≥80{\%} achieved between 6 and 76 months post transplant (median, 36 months). These data compare acceptably with the survival rates of related-donor BMT for thalassaemia and suggest that patients without an available HLA-compatible sibling but who have well-matched unrelated donors should also be considered for CBT.",
keywords = "cord blood transplantation, thalassaemia, unrelated donor",
author = "Jaing, {T. H.} and Hung, {I. J.} and Yang, {C. P.} and Chen, {S. H.} and Chung, {H. T.} and Tsay, {P. K.} and Wen, {Y. C.}",
year = "2012",
month = "1",
doi = "10.1038/bmt.2011.39",
language = "English",
volume = "47",
pages = "33--39",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Unrelated cord blood transplantation for thalassaemia

T2 - A single-institution experience of 35 patients

AU - Jaing, T. H.

AU - Hung, I. J.

AU - Yang, C. P.

AU - Chen, S. H.

AU - Chung, H. T.

AU - Tsay, P. K.

AU - Wen, Y. C.

PY - 2012/1

Y1 - 2012/1

N2 - Our study was designed to prospectively determine whether or not unrelated cord blood transplantation (CBT) can produce outcomes comparable to related donor transplantation for children with β-thalassaemia. In 35 patients, 40 transplants were performed between October 2003 and September 2009. HLA matching at enrolment was 6/6 (n=8), 5/6 (n=16), 4/6 (n=27), or 3/6 (n=1) by low-resolution HLA-A, -B, and high-resolution DRB1. These patients received non-manipulated grafts without ex vivo expansion or T-cell depletion. The median number of nucleated and CD34+ cells infused was 7.8 × 107/kg (range, 2.8-14.7 × 107/kg) and 4.0 × 105/kg (range, 1.7-19.9 × 105/kg), respectively. The 5-year OS and thalassaemia-free survival after the first transplant were 88.3 and 73.9%, respectively. The cumulative incidence of TRM at 2 years was 11.7%. Fourteen patients developed chronic skin GVHD. Thirty patients were alive and transfusion-independent with a Lansky performance score ≥80% achieved between 6 and 76 months post transplant (median, 36 months). These data compare acceptably with the survival rates of related-donor BMT for thalassaemia and suggest that patients without an available HLA-compatible sibling but who have well-matched unrelated donors should also be considered for CBT.

AB - Our study was designed to prospectively determine whether or not unrelated cord blood transplantation (CBT) can produce outcomes comparable to related donor transplantation for children with β-thalassaemia. In 35 patients, 40 transplants were performed between October 2003 and September 2009. HLA matching at enrolment was 6/6 (n=8), 5/6 (n=16), 4/6 (n=27), or 3/6 (n=1) by low-resolution HLA-A, -B, and high-resolution DRB1. These patients received non-manipulated grafts without ex vivo expansion or T-cell depletion. The median number of nucleated and CD34+ cells infused was 7.8 × 107/kg (range, 2.8-14.7 × 107/kg) and 4.0 × 105/kg (range, 1.7-19.9 × 105/kg), respectively. The 5-year OS and thalassaemia-free survival after the first transplant were 88.3 and 73.9%, respectively. The cumulative incidence of TRM at 2 years was 11.7%. Fourteen patients developed chronic skin GVHD. Thirty patients were alive and transfusion-independent with a Lansky performance score ≥80% achieved between 6 and 76 months post transplant (median, 36 months). These data compare acceptably with the survival rates of related-donor BMT for thalassaemia and suggest that patients without an available HLA-compatible sibling but who have well-matched unrelated donors should also be considered for CBT.

KW - cord blood transplantation

KW - thalassaemia

KW - unrelated donor

UR - http://www.scopus.com/inward/record.url?scp=84855738192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855738192&partnerID=8YFLogxK

U2 - 10.1038/bmt.2011.39

DO - 10.1038/bmt.2011.39

M3 - Article

C2 - 21383683

AN - SCOPUS:84855738192

VL - 47

SP - 33

EP - 39

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 1

ER -